Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 15/20 | 0.56 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.55 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803764 | 0.94 | DRD4 (0.60) | DRD4SLC6A12SLC6A13 | |
| SCHEMBL3774004 | 0.88 | DRD2 (0.51) | DRD4MCHR1 | |
| SCHEMBL3773750 | 0.86 | DRD2 (0.61) | DRD4 | |
| SCHEMBL3768127 | 0.86 | KMT2A (0.54) | DRD4 | |
| SCHEMBL3779258 | 0.85 | KMT2A (0.51) | DRD4 | |
| SCHEMBL3780573 | 0.85 | PKM (0.54) | DRD4MCHR1 | |
| SCHEMBL3762917 | 0.85 | USP2 (0.52) | DRD4 | |
| SCHEMBL3762907 | 0.84 | MCHR1 (0.58) | MCHR1 | |
| SCHEMBL3774288 | 0.84 | KMT2A (0.53) | DRD4 | |
| SCHEMBL3769105 | 0.83 | KMT2A (0.51) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | DRD4 1242/4885SLC6A12 2780/4885SLC6A13 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.